| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.064 | 0.3 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.046 | 0.3 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | 0.047 | 0.3 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.045 | 0.3 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.3 |